Nucl Med Commun. 2009 Jan;30(1):5-15.

Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step.

Source

Clinical Trials Center, University Medical Center, Elsässer Str. 2, D-79110 Freiburg, Germany. andreas.otte@uniklinik-freiburg.de

Abstract

Radiolabeled immunotherapy (RIT) is becoming a significant step forward in the treatment management of non-Hodgkin's lymphoma (NHL). In this state-of-the-art review article, general details, practical and health economic aspects, and next steps of RIT in NHL are reviewed from the existing literature and latest abstracts. As 90Y-ibritumomab tiuxetan is the only marketed RIT in NHL in Europe, the special focus of this review is on 90Y-ibritumomab tiuxetan, although the whole spectrum of available RIT concepts is highlighted. There is strong evidence to suggest that RIT is not only a safe and efficacious add-on treatment option in third or second line to chemotherapy, but is also a convincing asset as first-line therapy in various indications of lymphoma.

PMID:: 19020470; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms

Publication Types

MeSH Terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Education

New England Research Institutes Inc.

Medical

Supplemental Content

Related citations

Review Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists. [Int J Radiat Oncol Biol Phys. 2006]
Review Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
Macklis RM, Pohlman B. Int J Radiat Oncol Biol Phys. 2006 Nov 1; 66(3):833-41. Epub 2006 Sep 11.
Review Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin). [J Exp Ther Oncol. 2004]
Review Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin).
White CA. J Exp Ther Oncol. 2004 Dec; 4(4):305-16.
Review Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma. [Clin Lymphoma. 2004]
Review Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Micallef IN. Clin Lymphoma. 2004 Oct; 5 Suppl 1:S27-32.
Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). [Semin Nucl Med. 2005]
Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
DeNardo GL. Semin Nucl Med. 2005 Jul; 35(3):202-11.
Review Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. [Clin Lymphoma. 2004]
Review Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Ansell SM, Schilder RJ, Pieslor PC, Gordon LI, Emmanouilides C, Vo K, Czuczman MS, Witzig TE, Theuer C, Molina A. Clin Lymphoma. 2004 Dec; 5(3):202-4.

See reviews... See all...

Cited by 1 PubMed Central article

Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma. [Onco Targets Ther. 2009]
Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma.
Lehnert M, Ludwig H, Zojer N. Onco Targets Ther. 2009 Feb 18; 2:199-208. Epub 2009 Feb 18.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step.
Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step.
Nucl Med Commun. 2009 Jan ;30(1):5-15.

PubMed
Chronic spinal pain: a randomized clinical trial comparing medication, acupunctu...
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Spine (Phila Pa 1976). 2003 Jul 15 ;28(14):1490-502; discussion 1502-3.

PubMed
Tear meniscus height, lower punctum lacrimale, and the tear lipid layer in norma...
Tear meniscus height, lower punctum lacrimale, and the tear lipid layer in normal aging.
Optom Vis Sci. 2006 Oct ;83(10):731-9.

PubMed
Emerging research on methamphetamine.
Emerging research on methamphetamine.
Curr Opin Psychiatry. 2005 May ;18(3):235-42.

PubMed
Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis s...
Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option critical limb ischemia patients.
Atherosclerosis. 2010 Feb ;208(2):473-9. Epub 2009 Aug 8 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: